Compare Eli Lilly And Co (LLY) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Eli Lilly And Co trades at $1,216.51 (market cap $1.04T), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Eli Lilly And Co is far larger — about 298.9× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays the higher dividend (1.06%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| LLY | ZGN | |
|---|---|---|
Market Cap | $1.04T | $3.48B |
Volume | 1,843,375 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $15.25 |
52-Week Low | $799.57 | $8.69 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.09T | $4.43B |
Dividend Yield | 0.59% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.
Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
